Positive readout? Public offering: Viridian plans to raise $175M on eye disease therapy data
A year and a half after rebranding, Viridian Therapeutics appears to have found a path forward.
On Monday, the Waltham, MA-based biotech reported initial data from its Phase I/II trial of thyroid eye disease (TED) — and the results, while only in one of three treatment arms, look promising thus far. Later in the day, Viridian followed up with a public offering of $175 million in both common and preferred stock.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.